Navigation Links
Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
Date:2/25/2008

American Society of Breast Surgeons Study

Represents Largest Patient Population to Date

BEDFORD, Mass., Feb. 25 /PRNewswire-FirstCall/ -- Hologic, Inc. (Nasdaq: HOLX) a diversified medical technologies company specializing in imaging systems, diagnostics, and interventional devices dedicated to serving the healthcare needs of women, today announced the publication of a study evaluating the Hologic MammoSite(R) Radiation Therapy System (RTS), one-, two- and three-years after treatment. The study by Frank A. Vicini, M.D., and others, published in the February 15, 2008, issue of Cancer(1), the peer- reviewed professional journal of the American Cancer Society, reports on treatment efficacy, cosmetic results and toxicities of patients enrolled in the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial.

The American Society of Breast Surgeons MammoSite Registry(2) includes a total of 1,440 patients with early stage breast cancer, who were undergoing breast-conserving therapy and were treated with MammoSite RTS between May 2002 and July 2004. Of the total, 87 percent of the patients had invasive breast cancer and 13 percent had been diagnosed with ductal carcinoma in situ (DCIS).

The authors presented a subset analysis of the first 400 cases enrolled in the study with a median follow-up of 37.5 months. The three-year actuarial rate of local or regional recurrence was less than 2 percent in this group. The percentage of breasts with good and/or excellent cosmetic results was 93 percent at 36 months. The authors also reported a three-year actuarial local control rate of 100 percent in the first 48 patients enrolled with DCIS.

An analysis of the overall registr
'/>"/>

SOURCE Hologic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
3. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
4. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
5. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
6. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
7. Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
8. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
11. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...EW YORK, July 24 /- MacroCh...nounced results of a Phase 2 clinical trial,involv...i-center,open-label efficacy and safety study of ...tment of onychomycosis (nail fungus). The composit...lete cure" defined as,negative mycology (negative ...
(Date:7/23/2008)...tudy results pending publication in July print edi...vailable on Web, INDIANAPOLIS, July 23 /PRNewswir...aluating the use of N-terminal pro-B-type natriure...ue of NT-proBNP for risk,stratification in predict...AE) in patients treated with non-steroidal anti-in...
(Date:7/23/2008)...OSTON, July 23 /- FluoroPharma Inc., ...g agents for the Positron Emission Tomography,(PET...FPET, its novel,Fluorine-18 labeled tracer for myo... second cardiovascular product to complete Phase I...ent, designed to assess the blood flow in the,hear...
(Date:7/23/2008)...EATTLE, July 23 /- Dendreon... it expects the Independent Data,Monitoring Commit...nalysis,of overall survival relating to the Compan...noCarcinoma Treatment, also known as D9902B) clini...is the Company,s investigational,active cellular i...
Breaking Medicine Technology:MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Largest Ever Regional AIDS Conference to Review Epidemic Status and Changing Challenges in the Response 18253 1Largest Ever Regional AIDS Conference to Review Epidemic Status and Changing Challenges in the Response 18253 2Largest Ever Regional AIDS Conference to Review Epidemic Status and Changing Challenges in the Response 18253 3Largest Ever Regional AIDS Conference to Review Epidemic Status and Changing Challenges in the Response 18253 4Stinger Systems Inc Settles With the SEC 3158 1Male seahorses are natures Mr Mom Texas A 26M researchers say 3155 1Male seahorses are natures Mr Mom Texas A 26M researchers say 3155 2Male seahorses are natures Mr Mom Texas A 26M researchers say 3155 3Male seahorses are natures Mr Mom Texas A 26M researchers say 3155 4Masimo to Present at Deutsche Bank 33rd Annual Health Care Conference 5057 1Masimo to Present at Deutsche Bank 33rd Annual Health Care Conference 5057 2
...ented at 2007 APA Meeting Also Showed No,Significa...COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-FirstC... - one examining the,effect of desvenlafaxine succ... symptoms associated with major depressive disorde...hat examined the,effect of desvenlafaxine succinat...
...7 Percent Reduction in Risk of Hospitalization,fro...PARK, Ill., May 22, 2007 /PRNewswire-FirstCall/ --...alysis of a pivotal study,presented at the Digesti... showing patients with moderate to severely active...b) maintenance,therapy were almost 60 percent less...
Other Medicine Technology:Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 2Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 3Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 4Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 5Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 6New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 2New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 3New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 4New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 5New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 6New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 7
(Date:7/25/2008)...Robert J. Reilly, Joins Aethon Team, PITTSBURGH, ...ethon.com ), the leading developer of mobile robot...ounced that Robert J. Reilly has,joined the compan...cer., Reilly, who was most recently Vice Presiden...ecialty Pharmacy Division, brings more than 30,yea...
(Date:7/25/2008)...an cause immune system changes , , FRIDA...linking gastroesophageal reflux disease (GERD) and...ical Center researchers. , An association betwe..., and since then studies have shown that between 5...xperience GERD symptoms. But the actual link betwe...
(Date:7/25/2008)...mation Association (DIA) and the Food and Drug Adm...iative (CPI) on the Move: Complexities and Challen...cal Path Transporter Workshop (October 2-3; North ... PA (PRWEB) July 25, 2005-- The http://www.diahom...he Food and Drug Administration (FDA) will host th...
(Date:7/24/2008)...wswire/ -- Speaker Nancy Pelosi,released the follo...Lantos,and Henry J. Hyde Global Leadership Against...on Act of 2008. The bill, which passed the Senate ... of 303 to 115 and will now go,the President for h...historic vote to pass landmark legislation to,reau...
Breaking Medicine News(10 mins):Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:People With GERD More Likely to Develop Asthma 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3Health News:Pelosi Statement on House Passage of Global AIDS Legislation 2
... have come out with study results that encourage h...er of lymph nodes// marked by the presence of tu...ollow up. This, researchers opine, may be a defini... was shown to be positively associated with risks ...
...to experts, the Victorian disease tuberculosis is ...ction Agency of UK show// an increase by 2 percent...gures, released ahead of World TB Day, which falls...rovisional and relate to England, Wales and Northe...
...tudy finds that traditional Chinese medical belief...jing, China.// Jacqueline Hom, a dental student a...A, USA), reports her findings today during the 85t...ternational Association for Dental Research. Over...
...Health Organisation (WHO) has claimed that the glo...r the first time since it declared TB a public hea...Control Report released today, two days before the...of the world's population struck by TB peaked in 2...
Other Medicine News:Health News:Doctors Warned to Keep Track of Tumorous Lymph Nodes 2Health News:TB Cases on the Rise 2Health News:Global Tuberculosis Epidemic Levelling Off - WHO 2
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
Medicine Products: